This Article Full Text Full Text (PDF) Submit a related Letter to the Editor Purchase Article View Shopping Cart Alert me when this article is cited Alert me when eLetters are posted Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Copyright Permission Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Kahaly, G. J. Articles by Hommel, G. Search for Related Content PubMed PubMed Citation Articles by Kahaly, G. J. Articles by Hommel, G.

Low- Versus High-Dose Radiotherapy for Graves’ Ophthalmopathy: A Randomized, Single Blind Trial

Departments of Endocrinology/Metabolism, Radiology (H.-P.R.), Ophthalmology (S.P.), and Medical Statistics (G.H.), Gutenberg University Hospital, Mainz, Germany

Address all correspondence and requests for reprints to: Prof. George J. Kahaly, University Hospital, Building 303, Mainz 55101, Germany. E-mail: kahaly{at}endokrinologie.klinik.uni-mainz.de

Orbital radiotherapy (Rx) is a commonly used treatment for Graves’ ophthalmopathy (GO), but controlled clinical trials evaluating different Rx doses and application forms have not been performed. In euthyroid patients with moderately severe GO, we randomly compared the efficacy and tolerability of three Rx protocols. Orbital Rx (telecobalt) was administered either in 20 divided fractions of 1 Gray (Gy) weekly over 20 weeks (group A) or in 10 fractions of 1 Gy (B) and 2 Gy (C) daily over 2 weeks. Before and 24 weeks after starting Rx, ophthalmic investigation and magnetic resonance imaging were performed. Response to therapy, defined as a significant amelioration of three objective parameters, was noted in 12 A (67%), 13 B (59%), and 12 C (55%) subjects (C vs. A, P = 0.007). Ophthalmic symptoms and signs regressed most in group A; changes in lid fissure width were -1.5, -0.5, and 0 mm in the A, B, and C groups, respectively (A vs. C, P = 0.005), whereas changes in intraocular pressure (upgaze) were -3, +1, and -1.5 mm Hg, respectively (A vs. B, P = 0.002). The median decreases in proptosis were -2 mm (A, P = 0.0001), -1.5 mm (B, P = 0.02), and -1 mm (C, P = 0.007; A vs. C, P = 0.0380. Visual acuity (+0.15; P = 0.02) and eye muscle motility (bulbar elevation, 30° vs. 37°, P = 0.03, A vs. C, P = 0.0020; abduction, 45 vs. 49°, P = 0.02; A vs. C, P = 0.017) improved in group A only. A significant change in all rectus muscle areas was noted in 14 A (78%), 12 B (55%), and 9 C (41%) subjects (C vs. A, P = 0.002). A decrease in the NOSPECS classes was observed in 12 A (67%), 13 B (59%), and 13 C (59%) patients (A vs. B/C, P = 0.01). Rx-induced conjunctivitis was not observed in group A, but was seen in 4 B (18%) and 8 C (36%) subjects (C vs. A, P = 0.003). At 24 weeks, satisfaction rates were 67%, 59%, and 55% in the A, B, and C groups, respectively (C vs. A, P = 0.008). Thus, in patients with moderately severe GO, similar response rates were observed for low and high Rx doses, but the 1 Gy/week protocol was more effective and better tolerated than the short arm regimens.

This article has been cited by other articles:

				L. Bartalena, L. Baldeschi, A. Dickinson, A. Eckstein, P. Kendall-Taylor, C. Marcocci, M. Mourits, P. Perros, K. Boboridis, A. Boschi, et al. Consensus statement of the European Group on Graves' orbitopathy (EUGOGO) on management of GO Eur. J. Endocrinol., March 1, 2008; 158(3): 273 - 285. [Full Text] [PDF]

				The European Group of Graves' Orbitopathy, P Perros, L Baldeschi, K Boboridis, A J Dickinson, A Hullo, G J Kahaly, P Kendall-Taylor, G E Krassas, C M Lane, et al. A questionnaire survey on the management of Graves' orbitopathy in Europe. Eur. J. Endocrinol., August 1, 2006; 155(2): 207 - 211. [Abstract] [Full Text] [PDF]

				G. J. Kahaly, S. Pitz, G. Hommel, and M. Dittmar Randomized, Single Blind Trial of Intravenous versus Oral Steroid Monotherapy in Graves' Orbitopathy J. Clin. Endocrinol. Metab., September 1, 2005; 90(9): 5234 - 5240. [Abstract] [Full Text] [PDF]

				L. Bartalena, C. Marcocci, and A. Pinchera Orbital Radiotherapy for Graves' Ophthalmopathy J. Clin. Endocrinol. Metab., January 1, 2004; 89(1): 13 - 14. [Full Text] [PDF]

				M. F. Prummel, C. B. Terwee, M. N. Gerding, L. Baldeschi, M. P. Mourits, L. Blank, F. W. Dekker, and W. M. Wiersinga A Randomized Controlled Trial of Orbital Radiotherapy Versus Sham Irradiation in Patients with Mild Graves' Ophthalmopathy J. Clin. Endocrinol. Metab., January 1, 2004; 89(1): 15 - 20. [Abstract] [Full Text] [PDF]

				M Ott, N Breiter, C F Albrecht, O Pradier, C F Hess, and H Schmidberger Can contrast enhanced MRI predict the response of Graves' ophthalmopathy to orbital radiotherapy? Br. J. Radiol., June 1, 2002; 75(894): 514 - 517. [Abstract] [Full Text] [PDF]

				E. Christiansen and A. Kofoed-Enevoldsen Graves' Ophthalmopathy J. Clin. Endocrinol. Metab., May 1, 2001; 86(5): 2327 - 2327. [Full Text]

				G. J. Kahaly, H. P. Rösler, S. Pitz, F. Krummenauer, and G. Hommel Radiotherapy for Graves' Ophthalmopathy J. Clin. Endocrinol. Metab., May 1, 2001; 86(5): 2327a - 2328. [Full Text]